Logo image of ENLV

ENLIVEX THERAPEUTICS LTD (ENLV) Stock Fundamental Analysis

NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD

1  -0.02 (-1.81%)

Fundamental Rating

2

ENLV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While ENLV has a great health rating, there are worries on its profitability. ENLV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENLV had negative earnings in the past year.
In the past year ENLV has reported a negative cash flow from operations.
ENLV had negative earnings in each of the past 5 years.
In the past 5 years ENLV always reported negative operating cash flow.
ENLV Yearly Net Income VS EBIT VS OCF VS FCFENLV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ENLV's Return On Assets of -63.54% is on the low side compared to the rest of the industry. ENLV is outperformed by 61.28% of its industry peers.
The Return On Equity of ENLV (-71.21%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.54%
ROE -71.21%
ROIC N/A
ROA(3y)-46.68%
ROA(5y)-44.78%
ROE(3y)-56.09%
ROE(5y)-57.3%
ROIC(3y)N/A
ROIC(5y)N/A
ENLV Yearly ROA, ROE, ROICENLV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENLV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENLV Yearly Profit, Operating, Gross MarginsENLV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENLV has more shares outstanding
Compared to 5 years ago, ENLV has more shares outstanding
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENLV Yearly Shares OutstandingENLV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ENLV Yearly Total Debt VS Total AssetsENLV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

ENLV has an Altman-Z score of -2.43. This is a bad value and indicates that ENLV is not financially healthy and even has some risk of bankruptcy.
ENLV has a Altman-Z score (-2.43) which is in line with its industry peers.
ENLV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.43
ROIC/WACCN/A
WACCN/A
ENLV Yearly LT Debt VS Equity VS FCFENLV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 9.71 indicates that ENLV has no problem at all paying its short term obligations.
ENLV's Current ratio of 9.71 is fine compared to the rest of the industry. ENLV outperforms 79.57% of its industry peers.
A Quick Ratio of 9.71 indicates that ENLV has no problem at all paying its short term obligations.
ENLV has a better Quick ratio (9.71) than 79.75% of its industry peers.
Industry RankSector Rank
Current Ratio 9.71
Quick Ratio 9.71
ENLV Yearly Current Assets VS Current LiabilitesENLV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

ENLV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ENLV will show a small growth in Earnings Per Share. The EPS will grow by 6.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.87%
EPS Next 2Y27.31%
EPS Next 3Y17.31%
EPS Next 5Y6.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENLV Yearly Revenue VS EstimatesENLV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
ENLV Yearly EPS VS EstimatesENLV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
Also next year ENLV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENLV Price Earnings VS Forward Price EarningsENLV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENLV Per share dataENLV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ENLV's earnings are expected to grow with 17.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.31%
EPS Next 3Y17.31%

More info and screens

0

5. Dividend

5.1 Amount

ENLV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEX THERAPEUTICS LTD

NASDAQ:ENLV (2/21/2025, 8:15:48 PM)

1

-0.02 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)N/A N/A
Inst Owners15.69%
Inst Owner Change-99.67%
Ins Owners5.59%
Ins Owner ChangeN/A
Market Cap21.99M
Analysts82.5
Price Target9.69 (869%)
Short Float %0.61%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.92%
Min EPS beat(2)-4.58%
Max EPS beat(2)36.41%
EPS beat(4)2
Avg EPS beat(4)-5.63%
Min EPS beat(4)-68.07%
Max EPS beat(4)36.41%
EPS beat(8)5
Avg EPS beat(8)0.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.19%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.54%
ROE -71.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.68%
ROA(5y)-44.78%
ROE(3y)-56.09%
ROE(5y)-57.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.71
Quick Ratio 9.71
Altman-Z -2.43
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.22%
Cap/Depr(5y)361.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y55.87%
EPS Next 2Y27.31%
EPS Next 3Y17.31%
EPS Next 5Y6.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.81%
OCF growth 3YN/A
OCF growth 5YN/A